Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Co    LLY

News SummaryMost relevantAll newsSector news 

Eli Lilly & Co. : Lilly to Discontinue Late-Stage Tabalumab RA Program on Lack of Efficacy

share with twitter share with LinkedIn share with facebook
share via e-mail
02/07/2013 | 07:59pm CET

--Lilly to discontinue rheumatoid arthritis Phase 3 program for tabalumab

--Company will take a first-quarter charge of about $50 million

--Tabalumab continues to be in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

(Updates with additional details, share movement)

   By Saabira Chaudhuri 

Eli Lilly & Co. (LLY) said it will discontinue the rheumatoid arthritis Phase 3 program for its drug, tabalumab, citing a lack of efficacy.

The announcement comes less than two months after the drug company said it would stop one of three late-stage registration studies of tabalumab due to insufficient efficacy. At the time, Lilly said it was continuing to evaluate tabalumab in two other Phase 3 rheumatoid-arthritis registration studies as well as an open-label extension study and several smaller studies.

Lilly on Thursday said it has decided to discontinue the development of tabalumab in its current rheumatoid-arthritis program based on the outcomes of two separate interim-futility analyses. All ongoing Phase 2 and Phase 3 rheumatoid-arthritis studies will be stopped.

"While we are obviously disappointed by these results in rheumatoid arthritis, we continue to believe that tabalumab could have significant potential for patients in other disease areas," said Dr. Eiry Roberts, vice president of autoimmune product development at Lilly.

The decision is expected to result in a first-quarter charge to research-and-development expenses of about $50 million.

A spokesperson for the company noted Tabalumab is still in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

The Indianapolis company is experiencing one of the steepest patent cliffs in the drug industry, grappling with recent and looming generic competition for top-selling drugs as a result of patent expirations. The company lost exclusivity for its former No. 1 product, Zyprexa, in October 2011, and it will lose U.S. patent protection for the blockbuster antidepressant Cymbalta this December.

Lilly is trying to replenish revenue lost to generic competition for the older drugs by bringing new products to market and by increasing sales of drugs that remain patent-protected.

Last month, Lilly said its fourth-quarter earnings slipped 3.6% as the drug maker recorded weaker revenue as sales of Zyprexa slid.

Shares of Lilly, which backed its view for the year, edged down 41 cents to $53.52 in recent trading. The stock has risen 36% in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ELI LILLY AND CO
03:26p ALDER BIOPHARMACEUTICALS : European Patent Dispute Spurs Buying Opportunity with..
02:01p ELI LILLY AND : U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce t..
12/03 ELI LILLY AND : to cut sales jobs in early 2017
12/02 ELI LILLY AND : Lupin partners Eli Lilly to market diabetes drug `Eglucent`
12/02 ELI LILLY AND : Lilly Confirms Date and Conference Call for 2017 Financial Guida..
12/02 LUPIN : and Eli Lilly expand partnership in India
12/01 ELI LILLY AND : Urgency for Critical Alzheimer's Disease Treatments Intensifies ..
12/01 ELI LILLY AND : Studies Conducted at Eli Lilly on Antidiabetic Agents Recently R..
12/01 ELI LILLY AND : Study Data from Eli Lilly Update Knowledge of Immunoglobulins (S..
12/01 ELI LILLY AND : Research Conducted at Eli Lilly Has Provided New Information abo..
More news
Sector news : Pharmaceuticals - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/04 WEEK IN REVIEW : Suzhou's Innovent Biologics Announces Record $260 Million Fundi..
12/02 ALZHEIMER'S DISEASE : Does THC Hold The Key To A Cure?
12/02 FDA OKs CV risk reduction claim for Lilly and BI's diabetes med Jardiance
12/02 Lilly to release updated guidance on December 15
11/29 Oramed Vs. Novo Nordisk In Race For Oral GLP-1
Financials ($)
Sales 2016 21 008 M
EBIT 2016 4 646 M
Net income 2016 3 086 M
Debt 2016 2 304 M
Yield 2016 3,04%
P/E ratio 2016 25,77
P/E ratio 2017 19,50
EV / Sales 2016 3,67x
EV / Sales 2017 3,52x
Capitalization 74 748 M
More Financials
Duration : Period :
Eli Lilly and Co Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Full-screen chart
Technical analysis trends ELI LILLY AND CO
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 85,4 $
Spread / Average Target 26%
Consensus details
EPS Revisions
More Estimates Revisions
John C. Lechleiter Chairman, President & Chief Executive Officer
Derica W. Rice Chief Financial Officer & EVP-Global Services
Thomas F. Bumol Senior VP-Biotechnology & Autoimmunity Research
Timothy J. Garnett Chief Medical Officer
Jan M. Lundberg Executive Vice President-Science & Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND CO-21.71%74 748
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-20.19%188 878
NOVARTIS AG-19.07%178 737
MERCK & CO., INC.15.73%168 544
More Results